Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Pfizer	Eli Lilly and	Novo Nordisk A/S	Abbott Laboratories	Merck & Co., Inc.
Symbol	NYSE:PFE	NYSE:LLY	NYSE:NVO	NYSE:ABT	NYSE:MRK
Price Information
Current Price	$51.48	$246.33	$107.75	$132.47	$73.42
50-Day Moving Average	$46.45	$248.37	$106.49	$124.21	$81.01
52-Week Low	$33.36	$146.48	$66.59	$105.32	$70.89
52-Week High	$55.70	$275.87	$115.95	$133.28	$91.40
MarketRank™
Overall Score	3.1	3.0	2.2	2.8	3.5
Analysis Score	2.2	3.5	4.2	2.4	4.3
Community Score	4.8	4.8	4.0	4.8	4.5
Dividend Score	4.2	3.3	1.7	4.2	4.2
Ownership Score	2.5	2.5	0.0	2.5	2.5
Earnings & Valuation Score	1.9	0.6	1.3	0.0	1.9
Analyst Ratings
Consensus Recommendation	Hold	Buy	Hold	Buy	Buy
Consensus Price Target	$50.53	$272.71	$592.00	$136.57	$95.27
% Upside from Price Target	-1.84% downside	10.71% upside	449.42% upside	3.10% upside	29.76% upside
Trade Information
Market Cap	$288.95 billion	$235.64 billion	$253.73 billion	$234.24 billion	$185.45 billion
Beta	0.68	0.35	0.44	0.7	0.48
Average Volume	31,733,305	3,366,276	962,410	5,356,442	12,673,553
Sales & Book Value
Annual Revenue	$41.91 billion	$24.54 billion	$19.45 billion	$34.61 billion	$47.99 billion
Price / Sales	6.89	9.60	13.05	6.77	3.86
Cashflow	$3.02 per share	$8.89 per share	$3.15 per share	$5.75 per share	$7.35 per share
Price / Cash	17.06	27.70	34.23	23.03	9.99
Book Value	$13.53 per share	$8.31 per share	$4.45 per share	$19.59 per share	$14.20 per share
Price / Book	3.80	29.64	24.21	6.76	5.17
Profitability
Net Income	$9.62 billion	$6.19 billion	$6.46 billion	$4.50 billion	$7.07 billion
EPS	$3.36	$6.56	$3.21	$4.03	$2.83
Trailing P/E Ratio	15.32	37.55	33.57	32.87	25.94
Forward P/E Ratio	11.22	30.19	29.85	28.31	10.69
P/E Growth	1.23	1.95	2.70	2.12	1.92
Net Margins	27.66%	21.52%	34.33%	17.12%	14.64%
Return on Equity (ROE)	30.70%	111.51%	73.70%	28.39%	48.21%
Return on Assets (ROA)	12.92%	16.21%	30.19%	13.15%	16.00%
Dividend
Annual Payout	$1.56	$3.40	$0.77	$1.80	$2.60
Dividend Yield	3.03%	1.38%	0.71%	1.36%	3.54%
Three-Year Dividend Growth	-10.94%	42.31%	13.65%	35.85%	31.22%
Payout Ratio	46.43%	51.83%	23.99%	44.67%	91.87%
Years of Consecutive Dividend Growth	11 Years	7 Years	N/A	49 Years	11 Years
Debt
Debt-to-Equity Ratio	0.48	1.95	0.19	0.50	0.64
Current Ratio	1.39	1.30	1.03	1.83	1.31
Quick Ratio	1.18	1.02	0.82	1.42	1.07
Ownership Information
Institutional Ownership Percentage	64.99%	81.56%	5.58%	72.46%	71.79%
Insider Ownership Percentage	0.05%	0.13%	0.07%	1.50%	0.32%
Miscellaneous
Employees	78,500	35,000	45,323	109,000	74,000
Shares Outstanding	5.61 billion	956.59 million	2.35 billion	1.77 billion	2.53 billion
Next Earnings Date	2/1/2022 (Estimated)	2/4/2022 (Estimated)	2/2/2022 (Estimated)	1/26/2022 (Estimated)	2/3/2022 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection finance.yahoo.com - December 6 at 5:56 PM
	Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use msn.com - December 6 at 12:56 PM
	Merck Supports Hiring Our Heroes Corporate Fellowship Program finance.yahoo.com - December 6 at 12:56 PM
	Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19 finance.yahoo.com - December 6 at 12:56 PM
	How millions of COVID vaccines are paid for finance.yahoo.com - December 6 at 12:56 PM
	UPDATE 1-Merck ties up with Thermo Fisher to make its COVID-19 pill in Canada finance.yahoo.com - December 6 at 12:56 PM
	COVID: NYC expands vaccine mandate to include children finance.yahoo.com - December 6 at 12:56 PM
	Omicron variant: We don’t need to go into panic mode right now, physician says finance.yahoo.com - December 6 at 12:56 PM
	Here's Why Merck Lost Nearly $40 Billion in Value During November finance.yahoo.com - December 4 at 11:20 PM
	Merck (NYSE:MRK) Is Paying Out A Larger Dividend Than Last Year nasdaq.com - December 4 at 1:19 PM
	Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To US$0.69 finance.yahoo.com - December 4 at 1:19 PM
	FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection finance.yahoo.com - December 3 at 11:06 PM
	Merck to supply up to 1 mln courses of COVID-19 pill to Canada finance.yahoo.com - December 3 at 6:05 PM
	Merck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pill finance.yahoo.com - December 3 at 6:05 PM
	UPDATE 1-Merck to supply up to 1 mln courses of COVID-19 pill to Canada finance.yahoo.com - December 3 at 6:05 PM
	Merck's Selloff Is an Overreaction finance.yahoo.com - December 3 at 1:04 PM
	Fighting for Health Equity From Inside the Health Care Industry finance.yahoo.com - December 3 at 1:04 PM
	Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan finance.yahoo.com - December 3 at 1:04 PM
	COVID: ‘We need to stop wearing cloth masks and go to N95s for all,’ expert says finance.yahoo.com - December 3 at 1:04 PM
	FDA advisers recommend Merck’s COVID-19 pill in close vote msn.com - December 2 at 8:27 PM
	Belgium in talks to buy 10,000 doses of Merck's COVID-19 pill, health minister says reuters.com - December 2 at 8:27 PM
	Merck says its COVID-19 drug should be effective against any variant reuters.com - December 2 at 8:27 PM
	What's Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill? nasdaq.com - December 2 at 8:27 PM
	4 Dependable Healthcare Stocks to Buy Hand Over Fist Right Now stocknews.com - December 1 at 6:54 PM
	Merck & Co. Inc. [MRK] Is Currently 0.03 below its 200 Period Moving Avg: What Does This Mean? dbtnews.com - December 1 at 1:03 PM
	FDA panel narrowly backs COVID-19 pill from Merck marketbeat.com - November 30 at 5:14 PM
	Panel weighs safety, effectiveness of Merck's COVID-19 pill marketbeat.com - November 30 at 12:44 PM
	Final US hurdle for Merck's COVID-19 pill: FDA panel review marketbeat.com - November 30 at 9:14 AM
	Merck & Co., Inc. (NYSE:MRK) Receives Buy Rating from SVB Leerink marketbeat.com - November 30 at 7:28 AM
	Pfizer agrees to let other companies make its COVID-19 pill marketbeat.com - November 16 at 7:05 AM
	Johnson & Johnson to split into 2, aim for faster growth marketbeat.com - November 12 at 11:42 AM
	Johnson & Johnson to split into 2 companies marketbeat.com - November 12 at 9:05 AM
	3 COVID Stock Plays That Are Here to Stay (MRK) marketbeat.com - November 5 at 6:32 AM
	Is it Time to Get into Merck Shares? marketbeat.com - October 19 at 12:38 PM
	The Top 3 Buy & Hold Healthcare Stocks for October (MRK) marketbeat.com - October 6 at 8:35 PM
	Is American Airlines Stock Ready to Take Off? (MRK) marketbeat.com - October 3 at 10:50 PM

Date	Company	Brokerage	Action
11/30/2021	Merck & Co., Inc.	SVB Leerink	Reiterated Rating
11/29/2021	Pfizer	JPMorgan Chase & Co.	Boost Price Target
11/29/2021	Pfizer	Morgan Stanley	Boost Price Target
11/29/2021	Merck & Co., Inc.	Morgan Stanley	Lower Price Target
11/29/2021	Merck & Co., Inc.	Citigroup	Downgrade
11/24/2021	Pfizer	Truist Securities	Boost Price Target
11/24/2021	Pfizer	Truist	Boost Price Target
11/24/2021	Eli Lilly and	Truist Securities	Boost Price Target
11/24/2021	Eli Lilly and	Truist	Boost Price Target
11/24/2021	Merck & Co., Inc.	Truist Securities	Boost Price Target
11/24/2021	Merck & Co., Inc.	Truist	Boost Price Target
11/18/2021	Pfizer	BMO Capital Markets	Initiated Coverage
11/18/2021	Eli Lilly and	BMO Capital Markets	Initiated Coverage
11/18/2021	Merck & Co., Inc.	BMO Capital Markets	Initiated Coverage
11/17/2021	Pfizer	Barclays	Set Price Target
11/11/2021	Pfizer	Independent Research	Upgrade
11/11/2021	Novo Nordisk A/S	UBS Group	Reiterated Rating
11/5/2021	Pfizer	Cantor Fitzgerald	Reiterated Rating
11/5/2021	Pfizer	Benchmark	Boost Price Target
11/5/2021	Pfizer	JPMorgan Chase & Co.	Set Price Target
11/4/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
11/4/2021	Novo Nordisk A/S	Credit Suisse Group	Reiterated Rating
11/4/2021	Novo Nordisk A/S	JPMorgan Chase & Co.	Reiterated Rating
11/3/2021	Pfizer	Barclays	Set Price Target
11/3/2021	Pfizer	SVB Leerink	Lower Price Target
11/3/2021	Novo Nordisk A/S	Bryan, Garnier & Co	Downgrade
11/2/2021	Novo Nordisk A/S	Morgan Stanley	Reiterated Rating
11/1/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Reiterated Rating
11/1/2021	Merck & Co., Inc.	Barclays	Boost Price Target
11/1/2021	Merck & Co., Inc.	Argus	Upgrade
10/29/2021	Novo Nordisk A/S	DNB Markets	Downgrade
10/29/2021	Merck & Co., Inc.	Morgan Stanley	Boost Price Target
10/28/2021	Merck & Co., Inc.	Mizuho	Initiated Coverage
10/27/2021	Eli Lilly and	Mizuho	Lower Price Target
10/27/2021	Abbott Laboratories	Atlantic Securities	Upgrade
10/22/2021	Merck & Co., Inc.	SVB Leerink	Boost Price Target
10/21/2021	Abbott Laboratories	Morgan Stanley	Boost Price Target
10/21/2021	Abbott Laboratories	SVB Leerink	Reiterated Rating
10/21/2021	Abbott Laboratories	Raymond James	Boost Price Target
10/18/2021	Novo Nordisk A/S	SEB Equities	Upgrade
10/14/2021	Abbott Laboratories	Redburn Partners	Initiated Coverage
10/12/2021	Pfizer	Morgan Stanley	Boost Price Target
10/12/2021	Merck & Co., Inc.	Morgan Stanley	Boost Price Target
10/11/2021	Eli Lilly and	Berenberg Bank	Upgrade
10/10/2021	Merck & Co., Inc.	Berenberg Bank	Reiterated Rating
10/8/2021	Abbott Laboratories	Cowen	Reiterated Rating
10/8/2021	Merck & Co., Inc.	Barclays	Boost Price Target
10/4/2021	Merck & Co., Inc.	SVB Leerink	Boost Price Target
10/3/2021	Pfizer	Mizuho	Reiterated Rating
10/1/2021	Abbott Laboratories	Citigroup	Boost Price Target
10/1/2021	Merck & Co., Inc.	Mizuho	Initiated Coverage
9/29/2021	Eli Lilly and	Citigroup	Upgrade
9/24/2021	Eli Lilly and	JPMorgan Chase & Co.	Reiterated Rating
9/20/2021	Pfizer	SVB Leerink	Boost Price Target
9/14/2021	Pfizer	SVB Leerink	Reiterated Rating
9/13/2021	Pfizer	JPMorgan Chase & Co.	Boost Price Target
9/7/2021	Merck & Co., Inc.	Morgan Stanley	Downgrade
9/3/2021	Novo Nordisk A/S	Berenberg Bank	Reiterated Rating
8/31/2021	Abbott Laboratories	BTIG Research	Boost Price Target
8/30/2021	Eli Lilly and	Cowen	Boost Price Target
8/23/2021	Novo Nordisk A/S	Credit Suisse Group	Reiterated Rating
8/23/2021	Novo Nordisk A/S	Citigroup	Reiterated Rating
8/23/2021	Abbott Laboratories	Cowen	Boost Price Target
8/17/2021	Novo Nordisk A/S	UBS Group	Reiterated Rating
8/11/2021	Novo Nordisk A/S	Morgan Stanley	Reiterated Rating
8/9/2021	Eli Lilly and	Argus	Boost Price Target
8/6/2021	Novo Nordisk A/S	JPMorgan Chase & Co.	Reiterated Rating
8/5/2021	Eli Lilly and	DZ Bank	Upgrade
8/5/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
8/5/2021	Novo Nordisk A/S	Bank of America	Upgrade
8/5/2021	Novo Nordisk A/S	DNB Markets	Upgrade
8/4/2021	Eli Lilly and	JPMorgan Chase & Co.	Boost Price Target
8/4/2021	Eli Lilly and	Morgan Stanley	Boost Price Target
8/4/2021	Eli Lilly and	Mizuho	Boost Price Target
8/3/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Reiterated Rating
7/30/2021	Pfizer	Mizuho	Boost Price Target
7/30/2021	Merck & Co., Inc.	SVB Leerink	Boost Price Target
7/29/2021	Pfizer	The Goldman Sachs Group	Set Price Target
7/29/2021	Pfizer	Morgan Stanley	Boost Price Target
7/29/2021	Pfizer	Royal Bank of Canada	Set Price Target
7/29/2021	Pfizer	SVB Leerink	Boost Price Target
7/27/2021	Pfizer	Truist	Initiated Coverage
7/27/2021	Eli Lilly and	Truist	Initiated Coverage
7/27/2021	Merck & Co., Inc.	Truist Securities	Initiated Coverage
7/27/2021	Merck & Co., Inc.	Truist	Initiated Coverage
7/23/2021	Abbott Laboratories	Morgan Stanley	Boost Price Target
7/23/2021	Abbott Laboratories	Credit Suisse Group	Boost Price Target
7/23/2021	Abbott Laboratories	Raymond James	Boost Price Target
7/20/2021	Abbott Laboratories	SVB Leerink	Boost Price Target
7/19/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
7/15/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Reiterated Rating
7/12/2021	Abbott Laboratories	Wells Fargo & Company	Boost Price Target
7/7/2021	Eli Lilly and	Mizuho	Reiterated Rating
7/6/2021	Eli Lilly and	Barclays	Boost Price Target
7/2/2021	Eli Lilly and	Truist Securities	Boost Price Target
7/2/2021	Eli Lilly and	Truist	Boost Price Target
6/24/2021	Eli Lilly and	Cantor Fitzgerald	Boost Price Target
6/24/2021	Eli Lilly and	Cowen	Boost Price Target
6/17/2021	Pfizer	Royal Bank of Canada	Boost Price Target
6/15/2021	Pfizer	Berenberg Bank	Reiterated Rating
6/15/2021	Eli Lilly and	JPMorgan Chase & Co.	Boost Price Target
6/14/2021	Eli Lilly and	The Goldman Sachs Group	Boost Price Target
6/9/2021	Merck & Co., Inc.	JPMorgan Chase & Co.	Lower Price Target
6/8/2021	Eli Lilly and	Truist Securities	Reiterated Rating
6/8/2021	Eli Lilly and	Truist Financial	Reiterated Rating
6/7/2021	Merck & Co., Inc.	Truist Securities	Lower Price Target
6/3/2021	Merck & Co., Inc.	SVB Leerink	Lower Price Target
6/2/2021	Abbott Laboratories	BTIG Research	Lower Price Target
6/2/2021	Abbott Laboratories	Credit Suisse Group	Lower Price Target
6/2/2021	Abbott Laboratories	Barclays	Lower Price Target
6/2/2021	Abbott Laboratories	Wells Fargo & Company	Lower Price Target
6/2/2021	Abbott Laboratories	Raymond James	Lower Price Target
6/2/2021	Abbott Laboratories	Morgan Stanley	Lower Price Target
6/2/2021	Abbott Laboratories	Citigroup	Reiterated Rating
5/24/2021	Abbott Laboratories	Barclays	Initiated Coverage
5/20/2021	Merck & Co., Inc.	Argus	Reiterated Rating
4/30/2021	Merck & Co., Inc.	SVB Leerink	Lower Price Target
4/28/2021	Eli Lilly and	Morgan Stanley	Lower Price Target
4/21/2021	Abbott Laboratories	Morgan Stanley	Boost Price Target
4/20/2021	Abbott Laboratories	William Blair	Reiterated Rating
4/15/2021	Abbott Laboratories	Atlantic Securities	Initiated Coverage
2/11/2021	Novo Nordisk A/S	UBS Group	Reiterated Rating
2/4/2021	Novo Nordisk A/S	Barclays	Reiterated Rating
1/20/2021	Novo Nordisk A/S	Credit Suisse Group	Downgrade
1/15/2021	Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft	Initiated Coverage

(Data available from 12/7/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources